These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Nanodiamonds facilitate killing of intracellular uropathogenic E. coli in an in vitro model of urinary tract infection pathogenesis. Iyer JK; Dickey A; Rouhani P; Kaul A; Govindaraju N; Singh RN; Kaul R PLoS One; 2018; 13(1):e0191020. PubMed ID: 29324795 [TBL] [Abstract][Full Text] [Related]
23. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis. Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574 [TBL] [Abstract][Full Text] [Related]
24. Features of uropathogenic Escherichia coli able to invade a prostate cell line. Longhi C; Comanducci A; Riccioli A; Ziparo E; Marazzato M; Aleandri M; Conte AL; Lepanto MS; Goldoni P; Conte MP New Microbiol; 2016 Apr; 39(2):146-9. PubMed ID: 27196555 [TBL] [Abstract][Full Text] [Related]
26. A flow cytometry-based assay for screening FimH antagonists. Scharenberg M; Abgottspon D; Cicek E; Jiang X; Schwardt O; Rabbani S; Ernst B Assay Drug Dev Technol; 2011 Oct; 9(5):455-64. PubMed ID: 21675870 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model. Habibi M; Asadi Karam MR; Bouzari S Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493 [TBL] [Abstract][Full Text] [Related]
28. Urinary tract infections caused by Pseudomonas aeruginosa: a minireview. Mittal R; Aggarwal S; Sharma S; Chhibber S; Harjai K J Infect Public Health; 2009; 2(3):101-11. PubMed ID: 20701869 [TBL] [Abstract][Full Text] [Related]
29. Modulation of host innate immune response in the bladder by uropathogenic Escherichia coli. Billips BK; Forrestal SG; Rycyk MT; Johnson JR; Klumpp DJ; Schaeffer AJ Infect Immun; 2007 Nov; 75(11):5353-60. PubMed ID: 17724068 [TBL] [Abstract][Full Text] [Related]
30. Escherichia coli mediated urinary tract infections: are there distinct uropathogenic E. coli (UPEC) pathotypes? Marrs CF; Zhang L; Foxman B FEMS Microbiol Lett; 2005 Nov; 252(2):183-90. PubMed ID: 16165319 [TBL] [Abstract][Full Text] [Related]
31. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice. Asadi Karam MR; Oloomi M; Mahdavi M; Habibi M; Bouzari S Vaccine; 2013 Feb; 31(8):1210-6. PubMed ID: 23306365 [TBL] [Abstract][Full Text] [Related]
32. Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract. Lane MC; Lockatell V; Monterosso G; Lamphier D; Weinert J; Hebel JR; Johnson DE; Mobley HL Infect Immun; 2005 Nov; 73(11):7644-56. PubMed ID: 16239569 [TBL] [Abstract][Full Text] [Related]